Regulatory timeline
Federal safety actions on COVID-19 vaccines, in order: signals, pauses, recommendations, warnings, label changes, restrictions and withdrawals — with whether each is still current, was superseded, or was a signal later evaluation did not confirm. A preliminary signal is never shown as an established finding.
Topic: All · Myocarditis and pericarditis · Blood clots and thrombosis with thrombocytopenia (TTS) · Stroke · Guillain-Barré syndrome
Agency: FDA · CDC
-
CDC and FDA report a preliminary ischemic-stroke signal for Pfizer's bivalent booster in people 65+
Product: Pfizer-BioNTech COVID-19 Vaccine, Bivalent · Population: People 65 and older
What changed: No change to recommendations; the signal was investigated in other databases.
CDC's Vaccine Safety Datalink flagged a possible increase in ischemic stroke 1–21 days after Pfizer's bivalent booster in people 65 and older. Medicare and VA analyses did not find an increased risk, and as data accumulated the agencies said the evidence did not support a safety issue.
A preliminary signal from near-real-time surveillance is not a finding; this one was not confirmed by other systems.
Thread: stroke signal
- Signal — CDC and FDA report a preliminary ischemic-stroke signal for Pfizer's bivalent booster in people 65+ Signal not confirmed